Korean Journal of Medicinal Crop Science (한국약용작물학회지)

The Korean Society of Medicinal Crop Science (한국약용작물학회)
권호 표지
DOI QR코드

DOI QR Code

Improvement Effect of Non-alcoholic Fatty Liver Disease by Curcuma longa L. Extract

강황 추출물의 비알코올성 지방간 질환 개선 효과

  • Lee, Young Seob (Department of Herbal Crop Research, NIHHS, RDA) ;
  • Lee, Dae Young (Department of Herbal Crop Research, NIHHS, RDA) ;
  • Kwon, Dong Yeul (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University) ;
  • Kang, Ok Hwa (Wonkwang Oriental Medicines Research Institute, Wonkwang University)
  • 이영섭 (농촌진흥청 국립원예특작과학원 인삼특작부 인삼특작이용팀) ;
  • 이대영 (농촌진흥청 국립원예특작과학원 인삼특작부 인삼특작이용팀) ;
  • 권동렬 (원광대학교 약학대학 한약학과) ;
  • 강옥화 (원광대학교 원광한약연구소)
  • Received : 2020.06.17
  • Accepted : 2020.07.29
  • Published : 2020.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with multiple metabolic disorders. The medicinal plant Curcuma longa L. is widely distributed in Asia and has been used to treat a spectrum diseases in clinical practice. To date, there are inadequate reports of the effects of C. longa 50% EtOH extract (CE) on NAFLD. Therefore, in this study, we evaluate the CE on an NAFLD animal and elucidate the mechanism of action. Methods and Results: C57BL/6J mice fed a methionine-choline deficient diet (MCD) were treated with CE or milk thistle, and changes in inflammation and stetosis were assessed. Experimental animals were divided into six group (n = 10); Normal, MCD, MCD + CE 50 mg/kg/day (CE 50), MCD + CE 100 mg/kg/day (CE 100), MCD + CE 150 mg/kg/day (CE 150), and the Control, MCD + Milk thistle 150 mg/kg/day (MT 150). Body weight, liver weight, liver function, and histological changes were assessed in experimental animals. Quantitative real-time polymerase chain reaction and western blot analyses were performed on samples collected after 4 weeks of treatment. We observed that CE administration improved MCD-diet-induced lipid accumulation, and triglyceride (TG) and total cholesterol (TC) levels in serum. Treatment with CE also decreased hepatic lipogenesis through modulation of the sterol regulatory element binding protein-1 (SREBP-1), CCAAT-enhancer binding protein α (C/EBPα), fatty acid synthase (FAS), and peroxisome proliferator-activated receptor γ (PPARγ) expresion. In addition, the use of CE increased adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and inhibited the up-regulation of toll-like receptor (TLR)-2 and TLR-4 signaling and the production of inflammatory mediators. Conclusions: In this report, we observed that CE regulated lipid accumulation in an MCD dietinduced NAFLD model by decreasing lipogenesis. These data suggeste that CE could effectively protect mice against MCD-induced NAFLD, by inhibiting the TLR-2 and TLR-4 signaling cascades.

Keywords

References

  1. Ahsan H, Parveen N, Khan NU and Hadi SM. (1999). Prooxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chemico-biological Interactions. 121:161-175. https://doi.org/10.1016/S0009-2797(99)00096-4
  2. Akira S and Takeda K. (2004). Toll-like receptor signalling. Nature Reviews Immunology. 4:499-511. https://doi.org/10.1038/nri1391
  3. Ammon HP and Wahl MA. (1991). Pharmacology of Curcuma longa. Planta Medica. 57:1-7. https://doi.org/10.1055/s-2006-960004
  4. Arrese M, Cabrera D, Kalergis AM and Feldstein AE. (2016). Innate immunity and inflammation in NAFLD/NASH. Digestive Diseases and Sciences. 61:1294-1303. https://doi.org/10.1007/s10620-016-4049-x
  5. Bacon BR, Farahvash MJ, Janney CG and Neuschwander- Tetri BA. (1994). Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology. 107:1103-1109. https://doi.org/10.1016/0016-5085(94)90235-6
  6. Bieghs V and Trautwein C. (2003). The innate immune response during liver inflammation and metabolic disease. Trends in Immunology. 34:446-452. https://doi.org/10.1016/j.it.2013.04.005
  7. Brunt EM. (2002). Alcoholic and nonalcoholic steatohepatitis. Clinics in Liver Disease. 6:399-420. https://doi.org/10.1016/S1089-3261(02)00002-8
  8. Choi SK. (2004). Growth characteristics of Curcuma longa L. in southern part of Korea. Korean Journal of Medicinal Crop Science. 12:85-88.
  9. Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E and Szabo G. (2011). Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology. 300:433-441. https://doi.org/10.1152/ajpgi.00163.2009
  10. Farmer SR. (2006). Transcriptional control of adipocyte formation. Cell Metabolism. 4:263-273. https://doi.org/10.1016/j.cmet.2006.07.001
  11. Gervois P, Torra IP, Fruchart JC and Staels B. (2000). Regulation of lipid and lipoprotein metabolism by PPAR activators. Clinical Chemistry and Laboratory Medicine. 38:3-11. https://doi.org/10.1515/CCLM.2000.002
  12. Hardie DG. (2007). AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nature Reviews. Molecular Cell Biology 8:774-785. https://doi.org/10.1038/nrm2249
  13. Herzig S and Shaw RJ. (2017). AMPK: Guardian of metabolism and mitochondrial homeostasis. Nature Reviews Molecular Cell Biology. 19:121-135. https://doi.org/10.1038/nrm.2017.95
  14. Kang OH, Kim SB, Seo YS, Joung DK, Mun SH, Choi JG, Lee YM, Kang DG, Lee HS and Kwon DY. (2013). Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. European Review for Medical and Pharmacological Sciences. 17:2578-2586.
  15. Kesar V and Odin JA. (2013). Toll-like receptors and liver disease. Liver International. 34:184-196. https://doi.org/10.1111/liv.12315
  16. Kim DS, Park SY and Kim JY. (2001). Curcuminoids from Curcuma longa L.(Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from ${\beta}A$(1-42) insult. Neuroscience Letters. 303:57-61. https://doi.org/10.1016/S0304-3940(01)01677-9
  17. Kim SB, Kang OH, Lee YS, Han SH, Ahn YS, Cha SW, Seo YS, Kong R and Kwon DY. (2016). Hepatoprotective effect and synergism of bisdemethoycurcumin against MCD dietinduced nonalcoholic fatty liver disease in mice. PLoS One. 11:e0147745. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147745 (cited by 2020 May 11).
  18. Kiziltas S, Ata P, Colak Y, Mesçi B, Senates E, Enc F, Ulasoglu C, Tuncer I and Oguz A. (2014). TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metabolic Syndrome and Related Disorders. 12:165-170. https://doi.org/10.1089/met.2013.0120
  19. Lee JH, Oh MW, Jang HD, Lee YJ, Jeong JT and Park CG. (2020). Growth characteristics of turmeric(Curcuma longa L.) germplasms and storage conditions of seed rhizomes. Korean journal of Medicinal Crop Science. 28:47-55. https://doi.org/10.7783/KJMCS.2020.28.1.47
  20. Lee RG. (1989). Nonalcoholic steatohepatitis: A study of 49 patients. Human Pathology. 20:594-598. https://doi.org/10.1016/0046-8177(89)90249-9
  21. Lee YJ, Kim AK, Kim OH, Lee CY, Lee HK, Jung SO, Lee SR, Kim HS, Kim IY, Yu IS and Jung K. (2016). Sulfur dioxide, heavy metal and curcumin contents in market-available turmeric(Curcuma longa L.). Korean Journal of Medicinal Crop Science. 24:121-128. https://doi.org/10.7783/KJMCS.2016.24.2.121
  22. Leevy CM. (1962). Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine. 41:249-278. https://doi.org/10.1097/00005792-196209000-00003
  23. Lu YC, Yeh WC and Ohashi PS. (2008). LPS/TLR4 signal transduction pathway. Cytokine. 42:145-151. https://doi.org/10.1016/j.cyto.2008.01.006
  24. Musi N. (2006). AMP-activated protein kinase and type 2 diabetes. Current Medicinal Chemistry. 13:583-589. https://doi.org/10.2174/092986706776055724
  25. O'Neill LAJ and Bowie AG. (2007). The family of five: TIRdomain- containing adaptors in Toll-like receptor signalling. Nature Reviews. Immunology. 7:353-364. https://doi.org/10.1038/nri2079
  26. Pessayre D, Berson A, Fromenty B and Mansouri A. (2001). Mitochondria in steatohepatitis. Seminars in Liver Disease. 21:57-70. https://doi.org/10.1055/s-2001-12929
  27. Sahebkar A, Chew GT and Watts GF. (2014). New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opinion on Pharmacotherapy. 15:493-503. https://doi.org/10.1517/14656566.2014.876992
  28. Seki E and Brenner DA. (2008). Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology. 48:322-335. https://doi.org/10.1002/hep.22306
  29. Tilg H and Moschen AR. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 52:1836-1846. https://doi.org/10.1002/hep.24001
  30. Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, Andreelli F and Foretz M. (2009). AMP-activated protein kinase in there gulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiologica. 196:81-98. https://doi.org/10.1111/j.1748-1716.2009.01970.x
  31. Wanless IR and Lentz JS. (1990). Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology. 12:1106-1110. https://doi.org/10.1002/hep.1840120505
  32. Weng SY and Schuppan D. (2013). AMPK regulates macrophage polarization in adipose tissue inflammation and NASH. Journal of Hepatology. 58:619-621. https://doi.org/10.1016/j.jhep.2012.09.031
  33. Yang Q, Huang J, Zhang Y, Wang Q, He X, Feng G, Wang W and Li Z. (2013). Effects of soothing liver and invigorating spleen recipes on the mRNA and protein expression of TLR4 in hepatic tissues of rats with NASH. Journal of Chinese Medicinal Materials. 36:78-84.